These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 19606725)

  • 1. [Perspectives in inflammatory bowel diseases treatment].
    Jalocha L; Wojtuń S; Dyrla P; Błaszak A; Wojtkowiak M; Zyśko B; Stelmaszuk T; Gil J
    Pol Merkur Lekarski; 2009 May; 26(155):556-8. PubMed ID: 19606725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Application of TNF-alpha blocker concentration assays in the treatment of inflammatory bowel diseases].
    Sipponen T; Kolho KL
    Duodecim; 2013; 129(5):499-505. PubMed ID: 23520893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of infliximab and other biologic agents in the inflammatory bowel diseases.
    Reddy JG; Loftus EV
    Gastroenterol Clin North Am; 2006 Dec; 35(4):837-55. PubMed ID: 17129816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical treatment of inflammatory bowel diseases.
    Van Assche G; Vermeire S; Rutgeerts P
    Curr Opin Gastroenterol; 2005 Jul; 21(4):443-7. PubMed ID: 15930985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel therapeutic options in the inflammatory bowel disease world.
    Noble A; Baldassano R; Mamula P
    Dig Liver Dis; 2008 Jan; 40(1):22-31. PubMed ID: 17988966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The future of inflammatory bowel disease care.
    Sandborn WJ
    Rev Gastroenterol Disord; 2009; 9(3):E69-77. PubMed ID: 19898267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Biologic therapies in inflammatory bowel disease: anti-TNF and new therapeutic targets].
    Flamant M; Bourreille A
    Rev Med Interne; 2007 Dec; 28(12):852-61. PubMed ID: 17628232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis.
    Lee LY; Sanderson JD; Irving PM
    Eur J Gastroenterol Hepatol; 2012 Sep; 24(9):1078-85. PubMed ID: 22647738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease.
    Chang JT; Lichtenstein GR
    Nat Clin Pract Gastroenterol Hepatol; 2006 Apr; 3(4):220-8. PubMed ID: 16582964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of immune-mediated extraintestinal manifestations of inflammatory bowel disease with infliximab.
    Barrie A; Plevy S
    Gastroenterol Clin North Am; 2006 Dec; 35(4):883-93. PubMed ID: 17129819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [TNF-alpha inhibitors in inflammatory bowel disease].
    Casellas i Jordà F
    Med Clin (Barc); 2004 Nov; 123(16):627-34. PubMed ID: 15546523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
    Hanauer SB
    Gut; 2007 Sep; 56(9):1181-3. PubMed ID: 17698862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conventional drug therapy for inflammatory bowel disease.
    Bryant RV; Brain O; Travis SP
    Scand J Gastroenterol; 2015 Jan; 50(1):90-112. PubMed ID: 25523560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease.
    Sandborn WJ
    Rev Gastroenterol Disord; 2005; 5(1):10-8. PubMed ID: 15741928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic therapy for inflammatory bowel disease.
    Ardizzone S; Bianchi Porro G
    Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies.
    Bendtzen K; Ainsworth M; Steenholdt C; Thomsen OØ; Brynskov J
    Scand J Gastroenterol; 2009; 44(7):774-81. PubMed ID: 19140087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biologic therapies in chronic inflammatory bowel diseases].
    Reenaers C; Louis E; Belaiche J
    Rev Med Liege; 2009; 64(5-6):301-4. PubMed ID: 19642463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Era of Anti-Tumor Necrosis Factor Is Over. What Do We Know, What Don't We Know, and What Do We Yearn to Know?
    Dwadasi S; Israel A; Rubin DT
    Gastrointest Endosc Clin N Am; 2019 Jul; 29(3):405-419. PubMed ID: 31078244
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunotherapy in inflammatory bowel disease.
    Ahluwalia JP
    Med Clin North Am; 2012 May; 96(3):525-44, x. PubMed ID: 22703854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
    Rutgeerts P; Van Assche G; Vermeire S
    Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.